Bristol Myers Squibb Reports 6% YOY Revenue Growth in Q1 2024, Driven by Eliquis and Reblozyl
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has reported a 6% year-on-year (YOY) increase...
CAR-T
GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a...
Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...
Blue Shield Biotech Faces Bankruptcy Proceedings After Missing Debt Payments
The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield...
Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment
The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...
IASO Biotherapeutics Gains FDA Nod for Fucaso CAR-T Study in Myasthenia Gravis
China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...
Legend Biotech’s Carvykti Secures FDA Approval for Expanded Use in Multiple Myeloma
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that the US Food and Drug Administration...
Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production
Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...
Novatim Immune Therapeutics’ KQ-2003 Gains Tacit Approval for POEMS Syndrome Clinical Trial in China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd, a China-based specialist in cancer immunotherapy, has received tacit...
IASO Biotherapeutics Gets NMPA Go-Ahead for BCMA-Targeted CAR-T Therapy Clinical Trial
IASO Biotherapeutics, a China-based biopharmaceutical company, has announced that it has received approval from the...
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...
FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma
An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...
Legend Biotech Reports Q4 and Full-Year 2023 Financials with Focus on Carvykti Milestones
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the fourth quarter and...
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...
CARsgen Launches BCMA-Targeted CAR-T Therapy in China with High Price Point
China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted...
Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE
The China Center for Drug Evaluation (CDE) website has indicated that Shanghai Fosun Pharmaceutical (Group)...
CARsgen Therapeutics’ BCMA-targeted CAR-T Cell Therapy Approved by China’s NMPA
CARsgen Therapeutics Holdings Ltd (HKG: 2171), a specialist in chimeric antigen receptor (CAR)-T cell therapies...